 William Gentry
| Title | Professor |
|---|
| Institution | University of Arkansas for Medical Sciences |
|---|
| Department | Anesthesiology, College of Medicine |
|---|
| Division | Anesthesiology Faculty |
|---|
| Address | B112 Biomedical Research I
325 S. Elm St.
Mail Slot # 515
Little Rock AR 72205
|
|---|
| Phone | 501-320-7601 |
|---|
| vCard | Download vCard |
|---|
|
|
|
| Title | Professor |
|---|
| Institution | University of Arkansas for Medical Sciences |
|---|
| Department | Pharmacology and Toxicology, College of Medicine |
|---|
|
|
|---|
|
 Research U01DA055481 (STEVENS, MISTY WARD)Sep 30, 2021 - Jul 31, 2024 NIH
OUTLAST - A First Multiple-Dose Efficacy Study of IXT-m200, an anti-METH Monoclonal Antibody, in Patients with METH Use Disorder
Role: Co-Investigator |
| U01DA053043 (GENTRY, WILLIAM)Sep 30, 2020 - Jun 30, 2023 NIH/Nati. Inst. on Drug Abuse - Pass Thourhg: InterveXion Therapeutics, LLC
Meth-OD: A Phase 2A Study of IXT-m200 in Methamphetamine Overdose Patients
Role Description: InterveXion proposes to test IXT-m200, an antibody that specifically binds methamphetamine to keep it in the
blood and out of the brain, in patients who come to the emergency department with symptoms of a
methamphetamine overdose, such as agitation.
Role: Co-Principal Investigator |
| U01DA051078 (GENTRY, WILLIAM)May 1, 2020 - Mar 31, 2023 NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
Optimization and testing of anti-methamphetamine antibody therapy to support
Role: Principal Investigator |
| U01DA045366 (GENTRY, WILLIAM)Oct 1, 2017 - Jul 31, 2021 NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy’
Role: Principal Investigator |
| U01DA035511 (OWENS, SAMUEL)Jun 1, 2017 - May 31, 2019 NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
A Methamphetamine Conjugate Vaccine: From Manufacturing to IND - Continuation - Continuation
Role: Co-Investigator |
| U01DA037593 (GENTRY, WILLIAM)Sep 15, 2014 - Jun 30, 2018 NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
Transition to Human Phase 1b Trials: Nonclinical Studies of an Anti-METH mAb
Role: Principal Investigator |
| R21DA031837 (OLIVETO, ALISON)May 1, 2012 - Aug 31, 2015 NIH/Nat. Inst. on Drug Abuse
Impact of CYP2D6 Phenotype on Response to Methamphetamine in Humans
Role: Co-Investigator |
| R01DA031944 (GENTRY, WILLIAM)Jul 15, 2011 - Jun 30, 2015 NIH/Nat. Inst. on Drug Abuse
First Human Studies of a Chimeric Anti-Methamphetamine Monoclonal Antibody
Role: Principal Investigator |
| RC2DA028915 (GENTRY, WILLIAM)Oct 1, 2009 - Aug 20, 2012 NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
Chimeric anti-Methamphetamine Monoclonal Antibody for Treatment of METH Toxicity
Role: Principal Investigator |
| R01DA026916 (GENTRY, WILLIAM)Sep 1, 2009 - Jul 31, 2013 NIH/Nat. Inst. on Drug Abuse
Monoamine Antagonist Therapies for Methamphetamine Abuse
Role: Principal Investigator |
| U01DA023900 (OWENS, SAMUEL)Sep 30, 2007 - Aug 31, 2013 NIH/Nat. Inst. on Drug Abuse
Active Immunization for Treating Methamphetamine Abuse
Role: Co-Investigator |
| R42DA017596 (GENTRY, WILLIAM)Jul 1, 2006 - Oct 31, 2010 NIH/Nat. Inst. on Drug Abuse - Pass Through: InterveXion Therapeutics, LLC
Development of Plant Derived Antibodies for Drug Abuse
Role: Principal Investigator |
| K08DA00339 (GENTRY, WILLIAM)May 1, 2002 - Apr 30, 2004 NIH/Nat. Inst. on Drug Abuse
Mechanisms of Onset & Offset of Rapid Stimulant Effects
Role: Principal Investigator |
| R01DA011560 (OWENS, SAMUEL)Jan 5, 1998 - Mar 31, 2012 NIH/Nat. Inst. on Drug Abuse
Antibody-based Therapy for Methamphetamine Abuse
Role: Co-Investigator |
| R01DA010017 (OLIVETO, ALISON)Sep 30, 1997 - Nov 30, 2012 NIH/Nat. Inst. on Drug Abuse
Opioid Antagonist Discrimination: A Model of Withdrawal
Role: Co-Investigator |
| R01DA007610 (OWENS, SAMUEL)Mar 1, 1992 - Jun 30, 2012 NIH/Nat. Inst. on Drug Abuse
Immunotherapy for Drug Abuse
Role: Co-Investigator |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
Don't see publications published under other names? Login to add alternative names.
-
Laurenzana EM, Stevens MW, Frank JC, Hambuchen MD, Hendrickson HP, White SJ, Williams DK, Owens SM, Gentry WB. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development. Hum Vaccin Immunother. 2014; 10(9):2638-47. PMID: 25483484.
-
White SJ, Hendrickson HP, Atchley WT, Laurenzana EM, Gentry WB, Williams DK, Owens SM. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. Drug Metab Dispos. 2014 Aug; 42(8):1285-91. PMID: 24839971.
-
Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014; 6(6):1649-56. PMID: 25484042.
-
Oliveto A, Mancino M, Sanders N, Cargile C, Guise JB, Bickel W, Gentry W Brooks. Effects of Prototypic Calcium Channel Blockers in Methadone-Maintained Humans Under a Naloxone Discrimination Procedure. Eur J Pharmacol. 2013.
-
Walker BL, Vander Schilden JL, Gentry W Brooks. Intraarticular Analgesia Using a Meperidine-Local Anesthetic Combination in Arthroscopic Knee Procedures. Chirurgia Kolana, Atroskopia, Traumatologia Sportowa. 2013; 8(1):21-27.
-
White SJ, Laurenzana EM, Hendrickson HP, Gentry WB, Owens SM. Gestation time-dependent pharmacokinetics of intravenous (+)-methamphetamine and (+)-amphetamine in rats. Drug Metab Disp. 2011; 39:1718-26.
-
Hubbard JJ, Laurenzana EM, Williams DK, Gentry WB, Owens SM. The Fate and Function of Therapeutic Anti-addiction Monoclonal Antibodies. J Pharmacol Exp Ther. 2011; 336:414-22.
-
Oliveto A, Gentry WB, Pruzinsky R, Gonsai K, Kosten TR, Martell B, Poling J. Behavioral Effects of Gamma-Hydroxybutyrate (GHB) in Humans. Behavioral Pharmacology. 2010; 21:332-342.
-
White SJ, Laurenzana EM, Gentry WB, Hendrickson HP, Williams DK, Ward KW, Owens SM. Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion. Toxicol Sci. 2009 Sep; 111(1):27-36. PMID: 19520673.
-
Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB. Anti-PCP Monoclonal Antibody Binding Capacity is not the Only Determinant of Effectiveness, Disproving the Concept that Antibody Capacity is easily Surmounted. Drug Metab Dispos. 2006; 34:906-912.
-
Gurley B, Hubbard MA, Williams DK, Thaden J, Tong Y, Gentry WB, Breen P, Carrier DJ, Cheboyina S. Assessing the Clinical Significance of Botanical Supplementation on Human Cytochrome P450 3A4 Activity: Comparison of Milk Thistle and Black Cohosh to rifampin and Clarithromycin. J Clin Pharmacol. 2006; 46:201-213.
-
Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM. Safety and Efficiency of an Anti-(+)-Methamphetamine Monoclonal IgG in the Protection against Cardiovascular and Central Nervous System Effects of (+)-Methamphetamine in Rats. International Immunopharmacology. 2006; 6:968-977.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2006 | 3 | | 2009 | 1 | | 2010 | 1 | | 2011 | 2 | | 2013 | 2 | | 2014 | 3 |
To return to the timeline, click here.
|
Gentry's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|